NCT06736262Phase 2Terminated

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Study sponsor: Jasper Therapeutics, Inc. · JSPR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-21Actual
Enrollment · participants67Actual
Source updated2026-08-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 13 Aug 2026. After: 21 Jul 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 90 participants (planned). After: 67 participants (actual).

Primary completion date changed

Before: 1 Dec 2026. After: 13 Aug 2026.

Recruitment status changed

Before: Enrolling by invitation. After: Active not recruiting.

Check registry source